---
audienceLevel: patient
cancerTypes:
- breast
- lung
- colorectal
- prostate
- pancreatic
- liver
- ovarian
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- pdq
- treatment
title: Intravenous Vitamin C (PDQ®) - NCI
url: https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq
version: v1
---

# Intravenous Vitamin C (PDQ®) - NCI

# Intravenous Vitamin C (PDQ®)–Health Professional Version

## Overview

[Go to Patient Version](/about-cancer/treatment/cam/patient/vitamin-c-pdq)

This [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) information summary provides an overview of the use of [intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) (IV) [vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov) (also known as ascorbate or L-[ascorbic acid](/Common/PopUps/popDefinition.aspx?id=439436&version=healthprofessional&language=English&dictionary=Cancer.gov)) as a treatment for people with cancer. This summary includes a brief history of early [clinical trials](/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=English&dictionary=Cancer.gov) of the use of IV vitamin C; reviews of [laboratory](/Common/PopUps/popDefinition.aspx?id=44512&version=healthprofessional&language=English&dictionary=Cancer.gov), [animal](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov), and human studies; and current clinical trials.

This summary contains the following key information:

- Vitamin C is an essential [nutrient](/Common/PopUps/popDefinition.aspx?id=44697&version=healthprofessional&language=English&dictionary=Cancer.gov) with [redox](/Common/PopUps/popDefinition.aspx?id=770929&version=healthprofessional&language=English&dictionary=Cancer.gov) functions at normal [physiologic](/Common/PopUps/popDefinition.aspx?id=45837&version=healthprofessional&language=English&dictionary=Cancer.gov) [concentrations](/Common/PopUps/popDefinition.aspx?id=683342&version=healthprofessional&language=English&dictionary=Cancer.gov).
- [Case series](/Common/PopUps/popDefinition.aspx?id=44006&version=healthprofessional&language=English&dictionary=Cancer.gov) and [observational studies](/Common/PopUps/popDefinition.aspx?id=286105&version=healthprofessional&language=English&dictionary=Cancer.gov) from the 1970s of patients with cancer who received IV vitamin C seemed to indicate a clinical benefit.
- Two early [randomized](/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=English&dictionary=Cancer.gov) [placebo-controlled](/Common/PopUps/popDefinition.aspx?id=44840&version=healthprofessional&language=English&dictionary=Cancer.gov) trials that used oral vitamin C (10 g/d) without IV vitamin C noted no [significant](/Common/PopUps/popDefinition.aspx?id=390271&version=healthprofessional&language=English&dictionary=Cancer.gov) differences between ascorbate-treated and [placebo](/Common/PopUps/popDefinition.aspx?id=46688&version=healthprofessional&language=English&dictionary=Cancer.gov)-treated groups for [symptoms](/Common/PopUps/popDefinition.aspx?id=45022&version=healthprofessional&language=English&dictionary=Cancer.gov), [performance status](/Common/PopUps/popDefinition.aspx?id=44174&version=healthprofessional&language=English&dictionary=Cancer.gov), or [survival](/Common/PopUps/popDefinition.aspx?id=44301&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Laboratory studies have reported that IV vitamin C has redox properties and decreased [cell proliferation](/Common/PopUps/popDefinition.aspx?id=46479&version=healthprofessional&language=English&dictionary=Cancer.gov) in [prostate](/Common/PopUps/popDefinition.aspx?id=445079&version=healthprofessional&language=English&dictionary=Cancer.gov), [pancreatic](/Common/PopUps/popDefinition.aspx?id=44521&version=healthprofessional&language=English&dictionary=Cancer.gov), [hepatocellular](/Common/PopUps/popDefinition.aspx?id=46363&version=healthprofessional&language=English&dictionary=Cancer.gov), [colon](/Common/PopUps/popDefinition.aspx?id=44237&version=healthprofessional&language=English&dictionary=Cancer.gov), [mesothelioma](/Common/PopUps/popDefinition.aspx?id=44323&version=healthprofessional&language=English&dictionary=Cancer.gov), and [neuroblastoma](/Common/PopUps/popDefinition.aspx?id=45418&version=healthprofessional&language=English&dictionary=Cancer.gov) [cell lines](/Common/PopUps/popDefinition.aspx?id=695994&version=healthprofessional&language=English&dictionary=Cancer.gov).
- IV vitamin C has been generally well tolerated in clinical trials.
- IV [administration](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov) of vitamin C of doses over 500 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov) produces much higher [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) concentrations of ascorbate than oral administration of the same dose.
- The use of IV vitamin C alone as ascorbate versus ascorbate formulations plus certain standard cancer therapies have been shown to be well tolerated in clinical trials.
- Two studies that used IV vitamin C in patients with cancer reported improved [quality of life](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=English&dictionary=Cancer.gov) and decreases in cancer-related toxicities.
- Although early observations from preclinical and clinical trials of IV vitamin C with and without conventional cancer therapies appear promising and the therapy well tolerated, these studies have several limitations due to lack of rigor in trial design.

Many of the medical and [scientific](/Common/PopUps/popDefinition.aspx?id=44724&version=healthprofessional&language=English&dictionary=Cancer.gov) terms used in this summary are hypertext linked (at first use in each section) to the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"), which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.

Reference citations in some [PDQ](/Common/PopUps/popDefinition.aspx?id=44271&version=healthprofessional&language=English&dictionary=Cancer.gov) cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the [National Cancer Institute](/Common/PopUps/popDefinition.aspx?id=44266&version=healthprofessional&language=English&dictionary=Cancer.gov).

## General Information

[Vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov) is an essential [nutrient](/Common/PopUps/popDefinition.aspx?id=44697&version=healthprofessional&language=English&dictionary=Cancer.gov) that has [redox](/Common/PopUps/popDefinition.aspx?id=770929&version=healthprofessional&language=English&dictionary=Cancer.gov) functions, is a cofactor for several [enzymes](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov), and plays an important role in the synthesis of [collagen](/Common/PopUps/popDefinition.aspx?id=44196&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_2.1)] A severe [deficiency](/Common/PopUps/popDefinition.aspx?id=321364&version=healthprofessional&language=English&dictionary=Cancer.gov) in vitamin C results in scurvy, which is associated with malaise, [lethargy](/Common/PopUps/popDefinition.aspx?id=476353&version=healthprofessional&language=English&dictionary=Cancer.gov), easy bruising, and spontaneous bleeding.[[2](#cit/section_2.2)] One of the effects of scurvy is a change in collagen structure to a thinner consistency. Normal consistency is achieved with [administration](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov) of vitamin C.

In the mid-20th century, a study hypothesized that [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) may be related to changes in [connective tissue](/Common/PopUps/popDefinition.aspx?id=44013&version=healthprofessional&language=English&dictionary=Cancer.gov), which may be a consequence of vitamin C deficiency.[[3](#cit/section_2.3)] A review of evidence published in 1974 suggested that high-[dose](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) [ascorbic acid](/Common/PopUps/popDefinition.aspx?id=439436&version=healthprofessional&language=English&dictionary=Cancer.gov) may increase host resistance and be a potential cancer [therapy](/Common/PopUps/popDefinition.aspx?id=44737&version=healthprofessional&language=English&dictionary=Cancer.gov).[[4](#cit/section_2.4)]

Vitamin C is synthesized from D-[glucose](/Common/PopUps/popDefinition.aspx?id=44033&version=healthprofessional&language=English&dictionary=Cancer.gov) or D-galactose by many plants and animals. However, humans lack the enzyme L-gulonolactone oxidase required for ascorbic acid synthesis and must obtain vitamin C through food or [supplements](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_2.1)]

Some companies distribute vitamin C as [dietary supplements](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=English&dictionary=Cancer.gov). In the United States, dietary supplements are regulated by the [U.S. Food and Drug Administration](/Common/PopUps/popDefinition.aspx?id=454785&version=healthprofessional&language=English&dictionary=Cancer.gov) (FDA) as a separate category from foods, cosmetics, and drugs. Unlike drugs, dietary supplements do not require premarket evaluation and approval by the FDA unless specific disease [prevention](/Common/PopUps/popDefinition.aspx?id=439419&version=healthprofessional&language=English&dictionary=Cancer.gov) or treatment claims are made. The quality and amount of ingredients in dietary supplements are also regulated by the FDA through Good Manufacturing Practices (GMPs). The FDA GMPs requires that every finished batch of dietary supplement meets each product specification for identity, purity, strength, composition, and limits on contamination that may [adulterate](/Common/PopUps/popDefinition.aspx?id=686042&version=healthprofessional&language=English&dictionary=Cancer.gov) dietary supplements. Because dietary supplements are not formally reviewed for manufacturing consistency every year, ingredients may vary considerably from lot to lot and there is no guarantee that ingredients claimed on product labels are present (or are present in the specified amounts). The FDA has not approved the use of high-dose vitamin C as a treatment for cancer.

###### References

1. Naidu KA: Vitamin C in human health and disease is still a mystery? An overview. Nutr J 2: 7, 2003. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14498993&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14498993&dopt=Abstract")
2. Padayatty S, Espey MG, Levine M: Vitamin C. In: Coates PM, Betz JM, Blackman MR, et al., eds.: Encyclopedia of Dietary Supplements. 2nd ed. Informa Healthcare, 2010, pp 821-31.
3. McCORMICK WJ: Cancer: a collagen disease, secondary to a nutritional deficiency. Arch Pediatr 76 (4): 166-71, 1959. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13638066&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13638066&dopt=Abstract")
4. Cameron E, Pauling L: The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem Biol Interact 9 (4): 273-83, 1974. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4609626&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4609626&dopt=Abstract")

## History

The earliest experience of using both [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) and [intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) (IV) [vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov) for [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) treatment was by a Scottish [surgeon](/Common/PopUps/popDefinition.aspx?id=44306&version=healthprofessional&language=English&dictionary=Cancer.gov), Ewan Cameron, and his colleague, Allan Campbell, in the 1970s.[[1](#cit/section_3.1)] This work led to a collaboration between Cameron and the Nobel Prize–winning chemist Linus Pauling, further promoting the potential of vitamin C [therapy](/Common/PopUps/popDefinition.aspx?id=44737&version=healthprofessional&language=English&dictionary=Cancer.gov) in cancer management.[[2](#cit/section_3.2),[3](#cit/section_3.3)] As a result, two [clinical trials](/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=English&dictionary=Cancer.gov) of oral vitamin C were conducted in the late 1970s and early 1980s.[[4](#cit/section_3.4),[5](#cit/section_3.5)] These two trials did not use IV vitamin C.

For more information about these early studies, see the [Human Studies](/about-cancer/treatment/cam/hp/vitamin-c-pdq#_16) section.

[Pharmacokinetic](/Common/PopUps/popDefinition.aspx?id=44324&version=healthprofessional&language=English&dictionary=Cancer.gov) studies later revealed substantial differences in the maximum achieved [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) [concentrations](/Common/PopUps/popDefinition.aspx?id=683342&version=healthprofessional&language=English&dictionary=Cancer.gov) of vitamin C based on the route of [administration](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov). When vitamin C is taken orally, [plasma](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=English&dictionary=Cancer.gov) concentrations of the vitamin are tightly controlled, with a peak achievable concentration less than 300 [µM](/Common/PopUps/popDefinition.aspx?id=372932&version=healthprofessional&language=English&dictionary=Cancer.gov). However, this tight control is bypassed with IV administration of the vitamin, resulting in very high levels of vitamin C plasma concentration (i.e., levels up to 20 [mM](/Common/PopUps/popDefinition.aspx?id=659791&version=healthprofessional&language=English&dictionary=Cancer.gov)).[[6](#cit/section_3.6),[7](#cit/section_3.7)] Further research suggests that [pharmacological](/Common/PopUps/popDefinition.aspx?id=463167&version=healthprofessional&language=English&dictionary=Cancer.gov) concentrations of ascorbate, such as those achieved with IV administration, may result in [cell](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) death in many [cancer cell lines](/Common/PopUps/popDefinition.aspx?id=695994&version=healthprofessional&language=English&dictionary=Cancer.gov).[[8](#cit/section_3.8)]

Health care [practitioners](/Common/PopUps/popDefinition.aspx?id=463164&version=healthprofessional&language=English&dictionary=Cancer.gov) attending [complementary and alternative medicine](/Common/PopUps/popDefinition.aspx?id=44964&version=healthprofessional&language=English&dictionary=Cancer.gov) conferences in 2006 and 2008 were surveyed about usage of high-dose IV vitamin C in patients. Of the 199 total respondents, 172 had administered vitamin C to patients. In general, IV vitamin C was commonly used to treat [infections](/Common/PopUps/popDefinition.aspx?id=45364&version=healthprofessional&language=English&dictionary=Cancer.gov), cancer, and [fatigue](/Common/PopUps/popDefinition.aspx?id=321374&version=healthprofessional&language=English&dictionary=Cancer.gov).[[9](#cit/section_3.9)]

###### References

1. Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4430016&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4430016&dopt=Abstract")
2. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1068480&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1068480&dopt=Abstract")
3. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=279931&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=279931&dopt=Abstract")
4. Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=384241&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=384241&dopt=Abstract")
5. Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3880867&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3880867&dopt=Abstract")
6. Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15068981&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15068981&dopt=Abstract")
7. Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18544557&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18544557&dopt=Abstract")
8. Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19254759&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19254759&dopt=Abstract")
9. Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20628650&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20628650&dopt=Abstract")

## Laboratory/Animal/Preclinical Studies

### *In Vitro* Studies

Numerous studies have demonstrated that supraphysiologic [concentrations](/Common/PopUps/popDefinition.aspx?id=683342&version=healthprofessional&language=English&dictionary=Cancer.gov) of [ascorbic acid](/Common/PopUps/popDefinition.aspx?id=439436&version=healthprofessional&language=English&dictionary=Cancer.gov) (0.1–100 [mM)](/Common/PopUps/popDefinition.aspx?id=659791&version=healthprofessional&language=English&dictionary=Cancer.gov) decrease [cell proliferation](/Common/PopUps/popDefinition.aspx?id=46479&version=healthprofessional&language=English&dictionary=Cancer.gov) in a variety of [cancer cell lines](/Common/PopUps/popDefinition.aspx?id=695994&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_4.1)-[5](#cit/section_4.5)] Specifically, decreases in [cell](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) proliferation after ascorbic acid treatment have been reported for [prostate](/Common/PopUps/popDefinition.aspx?id=445079&version=healthprofessional&language=English&dictionary=Cancer.gov),[[6](#cit/section_4.6)] [pancreatic](/Common/PopUps/popDefinition.aspx?id=44074&version=healthprofessional&language=English&dictionary=Cancer.gov),[[7](#cit/section_4.7),[8](#cit/section_4.8)] [hepatocellular](/Common/PopUps/popDefinition.aspx?id=46363&version=healthprofessional&language=English&dictionary=Cancer.gov),[[9](#cit/section_4.9)] [colon](/Common/PopUps/popDefinition.aspx?id=44237&version=healthprofessional&language=English&dictionary=Cancer.gov),[[10](#cit/section_4.10)] [mesothelioma](/Common/PopUps/popDefinition.aspx?id=44323&version=healthprofessional&language=English&dictionary=Cancer.gov),[[11](#cit/section_4.11)] and [neuroblastoma](/Common/PopUps/popDefinition.aspx?id=45418&version=healthprofessional&language=English&dictionary=Cancer.gov) [[12](#cit/section_4.12)] cell lines.

The potential mechanisms through which treatment with [pharmacological](/Common/PopUps/popDefinition.aspx?id=463167&version=healthprofessional&language=English&dictionary=Cancer.gov) [doses](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) of ascorbic acid may exert its effects on cancer cells have been extensively investigated. Several studies have demonstrated that the *[in vitro](/Common/PopUps/popDefinition.aspx?id=45733&version=healthprofessional&language=English&dictionary=Cancer.gov)* direct [cytotoxic](/Common/PopUps/popDefinition.aspx?id=44020&version=healthprofessional&language=English&dictionary=Cancer.gov) effect of ascorbic acid on various types of cancer cells is mediated through a [chemical](/Common/PopUps/popDefinition.aspx?id=643008&version=healthprofessional&language=English&dictionary=Cancer.gov) reaction that generates [hydrogen peroxide](/Common/PopUps/popDefinition.aspx?id=44113&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_4.1),[7](#cit/section_4.7),[13](#cit/section_4.13),[14](#cit/section_4.14)] Treating [colon cancer](/Common/PopUps/popDefinition.aspx?id=44237&version=healthprofessional&language=English&dictionary=Cancer.gov) cells with 2 mM to 3 mM of ascorbic acid resulted in downregulation of specificity protein (Sp) [transcription](/Common/PopUps/popDefinition.aspx?id=390290&version=healthprofessional&language=English&dictionary=genetic) factors, [iron](/Common/PopUps/popDefinition.aspx?id=446805&version=healthprofessional&language=English&dictionary=Cancer.gov) [metabolism](/Common/PopUps/popDefinition.aspx?id=46173&version=healthprofessional&language=English&dictionary=Cancer.gov) disruption, and Sp-regulated [genes](/Common/PopUps/popDefinition.aspx?id=45693&version=healthprofessional&language=English&dictionary=genetic) involved in cancer [progression](/Common/PopUps/popDefinition.aspx?id=44078&version=healthprofessional&language=English&dictionary=Cancer.gov).[[10](#cit/section_4.10),[15](#cit/section_4.15)] One study suggested that ascorbate-mediated prostate cancer cell death may occur through activation of an [autophagy](/Common/PopUps/popDefinition.aspx?id=561319&version=healthprofessional&language=English&dictionary=Cancer.gov) pathway.[[6](#cit/section_4.6)] Data from a 2018 study demonstrated that labile iron and hydrogen peroxide play important roles in the mechanisms of selective [toxicity](/Common/PopUps/popDefinition.aspx?id=445093&version=healthprofessional&language=English&dictionary=Cancer.gov) of ascorbate and induction of oxidative [DNA](/Common/PopUps/popDefinition.aspx?id=45671&version=healthprofessional&language=English&dictionary=genetic) damage/cancer cell death.[[16](#cit/section_4.16)] Another *in vitro* study found that ascorbic acid killed colorectal cancer cells with *KRAS* or *BRAF* [mutations](/Common/PopUps/popDefinition.aspx?id=46063&version=healthprofessional&language=English&dictionary=genetic) by inhibiting the [enzyme](/Common/PopUps/popDefinition.aspx?id=46081&version=healthprofessional&language=English&dictionary=Cancer.gov) glyceraldehyde 3-phosphate dehydrogenase.[[17](#cit/section_4.17)]

Differences in [chemosensitivity](/Common/PopUps/popDefinition.aspx?id=372925&version=healthprofessional&language=English&dictionary=Cancer.gov) to ascorbate treatment in [breast cancer](/Common/PopUps/popDefinition.aspx?id=444971&version=healthprofessional&language=English&dictionary=Cancer.gov) cell lines may depend on expression of the [sodium](/Common/PopUps/popDefinition.aspx?id=44731&version=healthprofessional&language=English&dictionary=Cancer.gov)-dependent [vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov) transporter 2 (SVCT-2).[[18](#cit/section_4.18)]

Research has suggested that pharmacological doses of ascorbic acid enhance the effects of the following:

- [Arsenic trioxide](/Common/PopUps/popDefinition.aspx?id=46018&version=healthprofessional&language=English&dictionary=Cancer.gov) on [ovarian cancer](/Common/PopUps/popDefinition.aspx?id=445074&version=healthprofessional&language=English&dictionary=Cancer.gov) cells.[[19](#cit/section_4.19)]
- [Gemcitabine](/Common/PopUps/popDefinition.aspx?id=508951&version=healthprofessional&language=English&dictionary=Cancer.gov) on pancreatic cancer cells.[[8](#cit/section_4.8)]
- A combination treatment of gemcitabine and [epigallocatechin-3-gallate](/Common/PopUps/popDefinition.aspx?id=687212&version=healthprofessional&language=English&dictionary=Cancer.gov) (EGCG) on mesothelioma cells.[[20](#cit/section_4.20)]

Findings from one study reported in 2012 suggested that high-dose ascorbate increases radiosensitivity of [glioblastoma multiforme](/Common/PopUps/popDefinition.aspx?id=45699&version=healthprofessional&language=English&dictionary=Cancer.gov) cells, resulting in more cell death than from radiation alone.[[21](#cit/section_4.21)]

However, not all studies combining vitamin C with [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=English&dictionary=Cancer.gov) have shown improved outcomes. Treating [leukemia](/Common/PopUps/popDefinition.aspx?id=45343&version=healthprofessional&language=English&dictionary=Cancer.gov) and [lymphoma](/Common/PopUps/popDefinition.aspx?id=45368&version=healthprofessional&language=English&dictionary=Cancer.gov) cells with dehydroascorbic acid (the [oxidized](/Common/PopUps/popDefinition.aspx?id=654996&version=healthprofessional&language=English&dictionary=Cancer.gov) form of vitamin C that increases levels of [intracellular](/Common/PopUps/popDefinition.aspx?id=44047&version=healthprofessional&language=English&dictionary=Cancer.gov) ascorbic acid) reduced the cytotoxic effects of various [antineoplastic](/Common/PopUps/popDefinition.aspx?id=44816&version=healthprofessional&language=English&dictionary=Cancer.gov) agents tested, including [doxorubicin](/Common/PopUps/popDefinition.aspx?id=560140&version=healthprofessional&language=English&dictionary=Cancer.gov), [methotrexate](/Common/PopUps/popDefinition.aspx?id=45393&version=healthprofessional&language=English&dictionary=Cancer.gov), and [cisplatin](/Common/PopUps/popDefinition.aspx?id=45230&version=healthprofessional&language=English&dictionary=Cancer.gov) (relative reductions in cytotoxicity ranged from 30% to 70%).[[22](#cit/section_4.22)] In another study, [multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=healthprofessional&language=English&dictionary=Cancer.gov) cells were treated with [bortezomib](/Common/PopUps/popDefinition.aspx?id=269133&version=healthprofessional&language=English&dictionary=Cancer.gov) and/or [plasma](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=English&dictionary=Cancer.gov) obtained from healthy volunteers who had taken [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) vitamin C [supplements](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=English&dictionary=Cancer.gov). Cells treated with a combination of bortezomib and volunteers’ plasma exhibited lower cytotoxicity than did cells treated with bortezomib alone.[[23](#cit/section_4.23)]

### Animal Studies

In 2007, researches showed that oral [N-acetylcysteine](/Common/PopUps/popDefinition.aspx?id=45797&version=healthprofessional&language=English&dictionary=Cancer.gov) and vitamin C, both thought to act predominantly as [antioxidants](/Common/PopUps/popDefinition.aspx?id=43997&version=healthprofessional&language=English&dictionary=Cancer.gov), may have antitumorigenic actions *[in vivo](/Common/PopUps/popDefinition.aspx?id=46352&version=healthprofessional&language=English&dictionary=Cancer.gov)* by decreasing levels of [hypoxia](/Common/PopUps/popDefinition.aspx?id=302460&version=healthprofessional&language=English&dictionary=Cancer.gov)-inducible factor-1, a [transcription](/Common/PopUps/popDefinition.aspx?id=390290&version=healthprofessional&language=English&dictionary=genetic) factor that targets [vascular endothelial growth factor](/Common/PopUps/popDefinition.aspx?id=44222&version=healthprofessional&language=English&dictionary=Cancer.gov) and plays a role in [angiogenesis](/Common/PopUps/popDefinition.aspx?id=46529&version=healthprofessional&language=English&dictionary=Cancer.gov).[[24](#cit/section_4.24)]

Studies have demonstrated [tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) growth inhibition after treatment with pharmacological ascorbate in [animal models](/Common/PopUps/popDefinition.aspx?id=43996&version=healthprofessional&language=English&dictionary=Cancer.gov) with the following:

- Pancreatic cancer.[[1](#cit/section_4.1),[7](#cit/section_4.7),[8](#cit/section_4.8)]
- [Liver cancer](/Common/PopUps/popDefinition.aspx?id=44242&version=healthprofessional&language=English&dictionary=Cancer.gov).[[3](#cit/section_4.3)]
- Prostate cancer.[[25](#cit/section_4.25)]
- [Sarcoma](/Common/PopUps/popDefinition.aspx?id=45562&version=healthprofessional&language=English&dictionary=Cancer.gov).[[26](#cit/section_4.26)]
- Mesothelioma.[[11](#cit/section_4.11)]
- Ovarian cancer.[[4](#cit/section_4.4)]

The effects of parenterally [administered](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov) ascorbic acid in combination with [standard treatments](/Common/PopUps/popDefinition.aspx?id=44930&version=healthprofessional&language=English&dictionary=Cancer.gov) on tumors have been investigated. In a [mouse model](/Common/PopUps/popDefinition.aspx?id=561606&version=healthprofessional&language=English&dictionary=Cancer.gov) of pancreatic cancer, the combination of gemcitabine (30 or 60 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov)/[kg](/Common/PopUps/popDefinition.aspx?id=44576&version=healthprofessional&language=English&dictionary=Cancer.gov) every 4 days) and [intraperitoneal](/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=English&dictionary=Cancer.gov) [injection](/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=English&dictionary=Cancer.gov) of ascorbate (4 [g](/Common/PopUps/popDefinition.aspx?id=373014&version=healthprofessional&language=English&dictionary=Cancer.gov)/kg daily) resulted in greater decreases in [tumor volume](/Common/PopUps/popDefinition.aspx?id=467873&version=healthprofessional&language=English&dictionary=Cancer.gov) and weight, compared with gemcitabine treatment alone.[[8](#cit/section_4.8)] A study of mouse models of ovarian cancer found that ascorbate enhanced the tumor inhibitory effect of [carboplatin](/Common/PopUps/popDefinition.aspx?id=45182&version=healthprofessional&language=English&dictionary=Cancer.gov) and [paclitaxel](/Common/PopUps/popDefinition.aspx?id=45258&version=healthprofessional&language=English&dictionary=Cancer.gov), [first-line](/Common/PopUps/popDefinition.aspx?id=346494&version=healthprofessional&language=English&dictionary=Cancer.gov) chemotherapy used in ovarian cancer.[[27](#cit/section_4.27)] One study working with [xenograft](/Common/PopUps/popDefinition.aspx?id=44095&version=healthprofessional&language=English&dictionary=Cancer.gov) models of [non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=healthprofessional&language=English&dictionary=Cancer.gov) and glioblastoma multiforme showed that the combination of chemotherapy (carboplatin for lung cancer and [temozolomide](/Common/PopUps/popDefinition.aspx?id=45387&version=healthprofessional&language=English&dictionary=Cancer.gov) for glioblastoma), radiation therapy, and pharmacologic ascorbate (4 g/kg/d) [intraperitoneal](/Common/PopUps/popDefinition.aspx?id=46339&version=healthprofessional&language=English&dictionary=Cancer.gov) [injection](/Common/PopUps/popDefinition.aspx?id=44678&version=healthprofessional&language=English&dictionary=Cancer.gov) resulted in prolonged survival compared with just the combination of chemotherapy and radiation therapy.[[15](#cit/section_4.15)]

A study explored the [efficacy](/Common/PopUps/popDefinition.aspx?id=346517&version=healthprofessional&language=English&dictionary=Cancer.gov) of parenterally injected ascorbate with gemcitabine or radiation treatment in a mouse sarcoma xenograft model. Treatment involved intraperitoneally administered doses of ascorbate (4 g/kg) combined with gemcitabine (60 mg/kg) or radiation therapy (12 Gy in 2 fractions). Compared with the [control group](/Common/PopUps/popDefinition.aspx?id=44149&version=healthprofessional&language=English&dictionary=Cancer.gov), the combination treatments produced significantly greater inhibition of tumor growth, greater [survival rate](/Common/PopUps/popDefinition.aspx?id=44301&version=healthprofessional&language=English&dictionary=Cancer.gov), and no increase in toxicity, suggesting cancer cell selective toxicity.[[16](#cit/section_4.16)]

There have also been reports of animal studies in which vitamin C has interfered with the anticancer activity of various drugs. In a study reported in 2008, [administration](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov) of dehydroascorbic acid to lymphoma-xenograft mice prior to doxorubicin treatment resulted in significantly larger tumors than did treatment with doxorubicin alone.[[22](#cit/section_4.22)] Notably, this study used dehydroascorbate, the oxidized form of vitamin C that is known to be transported actively into cells and then reduced to vitamin C, but is not routinely used. Treating multiple myeloma xenograft mice with a combination of [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) vitamin C and bortezomib resulted in significantly greater tumor volume than did treatment with bortezomib alone.[[23](#cit/section_4.23)] This increase in tumor volume was caused by a chemical reaction that occurs in the [gastrointestinal tract](/Common/PopUps/popDefinition.aspx?id=46189&version=healthprofessional&language=English&dictionary=Cancer.gov) but does not appear to be relevant to [intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) administration.

###### References

1. Chen P, Stone J, Sullivan G, et al.: Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med 51 (3): 681-7, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21672627&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21672627&dopt=Abstract")
2. Chen Q, Espey MG, Krishna MC, et al.: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102 (38): 13604-9, 2005. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16157892&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16157892&dopt=Abstract")
3. Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19254759&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19254759&dopt=Abstract")
4. Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18678913&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18678913&dopt=Abstract")
5. Frömberg A, Gutsch D, Schulze D, et al.: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 67 (5): 1157-66, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20694726&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20694726&dopt=Abstract")
6. Chen P, Yu J, Chalmers B, et al.: Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs 23 (4): 437-44, 2012. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22205155&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22205155&dopt=Abstract")
7. Du J, Martin SM, Levine M, et al.: Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16 (2): 509-20, 2010. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20068072&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20068072&dopt=Abstract")
8. Espey MG, Chen P, Chalmers B, et al.: Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50 (11): 1610-9, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21402145&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21402145&dopt=Abstract")
9. Lin ZY, Chuang WL: Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 64 (5): 348-51, 2010. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19932582&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19932582&dopt=Abstract")
10. Pathi SS, Lei P, Sreevalsan S, et al.: Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer 63 (7): 1133-42, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21919647&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21919647&dopt=Abstract")
11. Takemura Y, Satoh M, Satoh K, et al.: High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 394 (2): 249-53, 2010. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20171954&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20171954&dopt=Abstract")
12. Hardaway CM, Badisa RB, Soliman KF: Effect of ascorbic acid and hydrogen peroxide on mouse neuroblastoma cells. Mol Med Report 5 (6): 1449-52, 2012. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22469841&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22469841&dopt=Abstract")
13. Du J, Cullen JJ, Buettner GR: Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta 1826 (2): 443-57, 2012. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22728050&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22728050&dopt=Abstract")
14. Levine M, Padayatty SJ, Espey MG: Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2 (2): 78-88, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22332036&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22332036&dopt=Abstract")
15. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 32 (2): 268, 2017. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28810149&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28810149&dopt=Abstract")
16. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models. Redox Biol 14: 417-422, 2018. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29069637&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29069637&dopt=Abstract")
17. Yun J, Mullarky E, Lu C, et al.: Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350 (6266): 1391-6, 2015. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26541605&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26541605&dopt=Abstract")
18. Hong SW, Lee SH, Moon JH, et al.: SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene 32 (12): 1508-17, 2013. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22665050&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22665050&dopt=Abstract")
19. Ong PS, Chan SY, Ho PC: Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation. Int J Oncol 38 (6): 1731-9, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21455570&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21455570&dopt=Abstract")
20. Martinotti S, Ranzato E, Burlando B: In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro 25 (8): 1568-74, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21645609&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21645609&dopt=Abstract")
21. Herst PM, Broadley KW, Harper JL, et al.: Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med 52 (8): 1486-93, 2012. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22342518&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22342518&dopt=Abstract")
22. Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18829561&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18829561&dopt=Abstract")
23. Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19369963&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19369963&dopt=Abstract")
24. Gao P, Zhang H, Dinavahi R, et al.: HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12 (3): 230-8, 2007. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17785204&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17785204&dopt=Abstract")
25. Pollard HB, Levine MA, Eidelman O, et al.: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24 (3): 249-55, 2010 May-Jun. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20554995&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20554995&dopt=Abstract")
26. Yeom CH, Lee G, Park JH, et al.: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7: 70, 2009. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19671184&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19671184&dopt=Abstract")
27. Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24500406&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24500406&dopt=Abstract")

## Human/Clinical Studies

### Early Case Series Studies and Clinical Trials With Ascorbate Only

In the early 1970s, a [consecutive case series](/Common/PopUps/popDefinition.aspx?id=285747&version=healthprofessional&language=English&dictionary=Cancer.gov) was conducted in which 50 patients with [advanced cancer](/Common/PopUps/popDefinition.aspx?id=478743&version=healthprofessional&language=English&dictionary=Cancer.gov) were treated with [intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) (IV) and [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) [doses](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) of [ascorbic acid](/Common/PopUps/popDefinition.aspx?id=439436&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_5.1)] These patients began ascorbic acid treatment after [conventional therapies](/Common/PopUps/popDefinition.aspx?id=44198&version=healthprofessional&language=English&dictionary=Cancer.gov) were deemed unlikely to be effective. Patients received IV ascorbic acid (10 [g](/Common/PopUps/popDefinition.aspx?id=373014&version=healthprofessional&language=English&dictionary=Cancer.gov)/day for 10 consecutive days; some patients received higher doses), oral ascorbic acid (10 g/day), or both. The patients exhibited a wide variety of [responses](/Common/PopUps/popDefinition.aspx?id=44085&version=healthprofessional&language=English&dictionary=Cancer.gov) to treatment, including the following:

- No or minimal response.
- [Tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) [regression](/Common/PopUps/popDefinition.aspx?id=46039&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Tumor [hemorrhage](/Common/PopUps/popDefinition.aspx?id=373015&version=healthprofessional&language=English&dictionary=Cancer.gov).

However, the authors noted that lack of controls prevented definitive assignment of any beneficial responses to the ascorbic acid treatment.[[1](#cit/section_5.1)] A [case report](/Common/PopUps/popDefinition.aspx?id=44007&version=healthprofessional&language=English&dictionary=Cancer.gov) published in 1975 detailed one of the patients who had experienced tumor regression.[[2](#cit/section_5.2)] [Diagnosed](/Common/PopUps/popDefinition.aspx?id=46450&version=healthprofessional&language=English&dictionary=Cancer.gov) with reticulum [cell](/Common/PopUps/popDefinition.aspx?id=46476&version=healthprofessional&language=English&dictionary=Cancer.gov) [sarcoma](/Common/PopUps/popDefinition.aspx?id=45562&version=healthprofessional&language=English&dictionary=Cancer.gov), the patient exhibited improvement in well-being and resolution of [lung](/Common/PopUps/popDefinition.aspx?id=270740&version=healthprofessional&language=English&dictionary=Cancer.gov) masses after being treated with IV and oral ascorbic acid. When the patient's daily dose of ascorbic acid was reduced, some signs of the disease returned; however, [remission](/Common/PopUps/popDefinition.aspx?id=45867&version=healthprofessional&language=English&dictionary=Cancer.gov) was achieved again after the patient reverted to the higher initial dose.

A larger [case series](/Common/PopUps/popDefinition.aspx?id=44006&version=healthprofessional&language=English&dictionary=Cancer.gov) of patients with terminal cancer treated with ascorbate was reported in 1976. In this study, 100 patients with terminal cancer (50 of whom were reported on previously) [[1](#cit/section_5.1)] were treated with ascorbate (10 g/day for 10 days IV, then orally) and compared with 1,000 matched controls from the same hospital. The [mean survival](/Common/PopUps/popDefinition.aspx?id=285974&version=healthprofessional&language=English&dictionary=Cancer.gov) time for ascorbate-treated patients was 300 days longer than that of the matched controls.[[3](#cit/section_5.3),[4](#cit/section_5.4)]

Two studies tried to reproduce earlier results. These studies were [randomized](/Common/PopUps/popDefinition.aspx?id=45858&version=healthprofessional&language=English&dictionary=Cancer.gov), [placebo-controlled](/Common/PopUps/popDefinition.aspx?id=44840&version=healthprofessional&language=English&dictionary=Cancer.gov) trials in which patients with cancer received either 10 g of oral [vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov) or [placebo](/Common/PopUps/popDefinition.aspx?id=46688&version=healthprofessional&language=English&dictionary=Cancer.gov) daily until signs of cancer progression. No IV vitamin C was given in these studies. At the end of each study, no [significant](/Common/PopUps/popDefinition.aspx?id=390271&version=healthprofessional&language=English&dictionary=Cancer.gov) differences were noted between the two ascorbate-treated and placebo-treated groups for [symptoms](/Common/PopUps/popDefinition.aspx?id=45022&version=healthprofessional&language=English&dictionary=Cancer.gov), [performance status](/Common/PopUps/popDefinition.aspx?id=44174&version=healthprofessional&language=English&dictionary=Cancer.gov), or [survival](/Common/PopUps/popDefinition.aspx?id=44301&version=healthprofessional&language=English&dictionary=Cancer.gov).[[5](#cit/section_5.5),[6](#cit/section_5.6)]

### Recent Case Series Studies and Clinical Trials With Ascorbate Only

One study reported three case reports of patients with cancer who received IV vitamin C as their main [therapy](/Common/PopUps/popDefinition.aspx?id=44737&version=healthprofessional&language=English&dictionary=Cancer.gov). During vitamin C therapy, the patients used additional treatments, including [vitamins](/Common/PopUps/popDefinition.aspx?id=44744&version=healthprofessional&language=English&dictionary=Cancer.gov), [minerals](/Common/PopUps/popDefinition.aspx?id=45787&version=healthprofessional&language=English&dictionary=Cancer.gov), and [botanicals](/Common/PopUps/popDefinition.aspx?id=367458&version=healthprofessional&language=English&dictionary=Cancer.gov). According to the authors, the cases were reviewed in accordance with the  [NCI Best Case Series guidelines](https://cam.cancer.gov/indentifying_novel_cam_therapies/best_case_protocol.htm "https://cam.cancer.gov/indentifying_novel_cam_therapies/best_case_protocol.htm"). [Histopathologic](/Common/PopUps/popDefinition.aspx?id=467841&version=healthprofessional&language=English&dictionary=Cancer.gov) examination suggested poor [prognoses](/Common/PopUps/popDefinition.aspx?id=45849&version=healthprofessional&language=English&dictionary=Cancer.gov) for these patients, but they had long survival times after being treated with IV vitamin C.[[7](#cit/section_5.7)] Vitamin C was given at doses ranging from 15 g to 65 g, initially once or twice a week for several months; two patients then received it less frequently for 1 to 4 years.

One study demonstrated that IV vitamin C treatment resulted in improved [quality of life](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=English&dictionary=Cancer.gov) and a decrease in cancer-related [side effects](/Common/PopUps/popDefinition.aspx?id=46580&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients with cancer.[[8](#cit/section_5.8)]

A single-arm [pilot study](/Common/PopUps/popDefinition.aspx?id=45838&version=healthprofessional&language=English&dictionary=Cancer.gov) of weekly [infusions](/Common/PopUps/popDefinition.aspx?id=45738&version=healthprofessional&language=English&dictionary=Cancer.gov) of 60 g of ascorbic acid for 9 weeks in patients with [castration](/Common/PopUps/popDefinition.aspx?id=45636&version=healthprofessional&language=English&dictionary=Cancer.gov)-resistant [prostate cancer](/Common/PopUps/popDefinition.aspx?id=445079&version=healthprofessional&language=English&dictionary=Cancer.gov) failed to observe a [reduction](/Common/PopUps/popDefinition.aspx?id=654999&version=healthprofessional&language=English&dictionary=Cancer.gov) in [serum](/Common/PopUps/popDefinition.aspx?id=44088&version=healthprofessional&language=English&dictionary=Cancer.gov) [prostate-specific antigen](/Common/PopUps/popDefinition.aspx?id=46540&version=healthprofessional&language=English&dictionary=Cancer.gov) or tumor regression.[[9](#cit/section_5.9)]

Studies have shown that vitamin C can be safely administered to healthy volunteers or patients with cancer at doses up to 1.5 g/[kg](/Common/PopUps/popDefinition.aspx?id=44576&version=healthprofessional&language=English&dictionary=Cancer.gov) and with [screening](/Common/PopUps/popDefinition.aspx?id=46171&version=healthprofessional&language=English&dictionary=genetic) to eliminate treating individuals with [risk factors](/Common/PopUps/popDefinition.aspx?id=45873&version=healthprofessional&language=English&dictionary=Cancer.gov) for [toxicity](/Common/PopUps/popDefinition.aspx?id=445093&version=healthprofessional&language=English&dictionary=Cancer.gov) (e.g., [glucose-6-phosphate dehydrogenase deficiency](/Common/PopUps/popDefinition.aspx?id=748114&version=healthprofessional&language=English&dictionary=Cancer.gov), renal diseases, or urolithiasis). These studies have also found that [plasma](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=English&dictionary=Cancer.gov) [concentrations](/Common/PopUps/popDefinition.aspx?id=683342&version=healthprofessional&language=English&dictionary=Cancer.gov) of vitamin C are higher with IV [administration](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov) than with oral administration and are maintained for more than 4 hours.[[10](#cit/section_5.10),[11](#cit/section_5.11)]

### Early Phase Ascorbate Trials Combined With Standard Cancer Therapies

A [phase I](/Common/PopUps/popDefinition.aspx?id=45830&version=healthprofessional&language=English&dictionary=Cancer.gov) study published in 2012 examined the safety and [efficacy](/Common/PopUps/popDefinition.aspx?id=346517&version=healthprofessional&language=English&dictionary=Cancer.gov) of combining IV ascorbate with [gemcitabine](/Common/PopUps/popDefinition.aspx?id=508951&version=healthprofessional&language=English&dictionary=Cancer.gov) and [erlotinib](/Common/PopUps/popDefinition.aspx?id=508929&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients with [stage IV pancreatic cancer](/Common/PopUps/popDefinition.aspx?id=45511&version=healthprofessional&language=English&dictionary=Cancer.gov). Fourteen patients entered the study and planned to receive IV gemcitabine (1,000 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov)/m2 over 30 minutes, once a week for 7 weeks), oral erlotinib (100 mg daily for 8 weeks), and IV ascorbate (50 g/[infusion](/Common/PopUps/popDefinition.aspx?id=45738&version=healthprofessional&language=English&dictionary=Cancer.gov), 75 g/infusion, or 100 g/infusion 3 times per week for 8 weeks). Minimal [adverse effects](/Common/PopUps/popDefinition.aspx?id=44922&version=healthprofessional&language=English&dictionary=Cancer.gov) were reported for ascorbic acid treatment. Five patients received fewer than 18 of the planned 24 ascorbate infusions and thus did not have [follow-up](/Common/PopUps/popDefinition.aspx?id=44671&version=healthprofessional&language=English&dictionary=Cancer.gov) [imaging](/Common/PopUps/popDefinition.aspx?id=46361&version=healthprofessional&language=English&dictionary=Cancer.gov) to assess response. Three of those patients had clinically determined [progressive disease](/Common/PopUps/popDefinition.aspx?id=45850&version=healthprofessional&language=English&dictionary=Cancer.gov). The other nine patients had repeat imaging to assess tumor size, and each met the criteria for having [stable disease](/Common/PopUps/popDefinition.aspx?id=45884&version=healthprofessional&language=English&dictionary=Cancer.gov).[[12](#cit/section_5.12)]

A 2013 phase I [clinical study](/Common/PopUps/popDefinition.aspx?id=44195&version=healthprofessional&language=English&dictionary=Cancer.gov) ([NCT01049880](/clinicaltrials/NCT01049880)) evaluated the safety of combining pharmacological ascorbate with gemcitabine in treating patients with stage IV pancreatic cancer. During each 4-week cycle, patients received gemcitabine weekly for 3 weeks (1,000 mg/m2 over 30 minutes) and twice-weekly ascorbate infusions for 4 weeks (15 g over 30 minutes during the first week, followed by weekly escalations in dose until plasma levels reached at least 350 mg/dL [20 [mM](/Common/PopUps/popDefinition.aspx?id=659791&version=healthprofessional&language=English&dictionary=Cancer.gov)]). Among nine patients, mean [progression-free survival](/Common/PopUps/popDefinition.aspx?id=44782&version=healthprofessional&language=English&dictionary=Cancer.gov) (PFS) was 26 weeks and [overall survival](/Common/PopUps/popDefinition.aspx?id=655245&version=healthprofessional&language=English&dictionary=Cancer.gov) (OS) was 12 months. The combination treatment was well tolerated, and no significant adverse events were reported.[[13](#cit/section_5.13)]

In 2014, a [phase I/IIA](/Common/PopUps/popDefinition.aspx?id=45832&version=healthprofessional&language=English&dictionary=Cancer.gov) clinical trial evaluated the toxicities of combining IV ascorbate with [carboplatin](/Common/PopUps/popDefinition.aspx?id=45182&version=healthprofessional&language=English&dictionary=Cancer.gov) and [paclitaxel](/Common/PopUps/popDefinition.aspx?id=45258&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients with [stage III](/Common/PopUps/popDefinition.aspx?id=45901&version=healthprofessional&language=English&dictionary=Cancer.gov)/[IV ovarian cancer](/Common/PopUps/popDefinition.aspx?id=45902&version=healthprofessional&language=English&dictionary=Cancer.gov). Twenty-seven patients were randomly assigned to receive either [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=English&dictionary=Cancer.gov) alone or chemotherapy and IV vitamin C concurrently. Chemotherapy was given for 6 months, and IV vitamin C was given for 12 months. The addition of IV vitamin C was associated with reduced chemotherapy-related toxicities.[[14](#cit/section_5.14)]

A 2015 phase I/II clinical trial of high-dose IV vitamin C (approximately 1.5 g/kg body weight) combined with various chemotherapies, depending on the specific cancer diagnosis, was conducted to do the following:[[15](#cit/section_5.15)]

- Observe the associated adverse events.
- Assess the [pharmacokinetic](/Common/PopUps/popDefinition.aspx?id=44324&version=healthprofessional&language=English&dictionary=Cancer.gov) profiles of vitamin C and oxalic acid levels prechemotherapy- and postchemotherapy.
- Assess [clinical](/Common/PopUps/popDefinition.aspx?id=44168&version=healthprofessional&language=English&dictionary=Cancer.gov) responses.
- Assess changes in mood.
- Assess changes in quality of life.

High-dose IV vitamin C was analyzed in 14 patients and was generally well tolerated and safe. Minor temporary adverse effects included increased [urinary](/Common/PopUps/popDefinition.aspx?id=44093&version=healthprofessional&language=English&dictionary=Cancer.gov) flow, thirst, [nausea](/Common/PopUps/popDefinition.aspx?id=390302&version=healthprofessional&language=English&dictionary=Cancer.gov), [vomiting](/Common/PopUps/popDefinition.aspx?id=390324&version=healthprofessional&language=English&dictionary=Cancer.gov), and chills, some of which could be prevented. Chemotherapy administration did not affect the plasma concentration of vitamin C. Although a few patients experienced temporary stable disease, functional improvement, and increased energy, the sample size is so small that the generalizability of these results is uncertain.[[15](#cit/section_5.15)]

In 2017, a phase I/IIA study reported using IV vitamin C with [standard-of-care](/Common/PopUps/popDefinition.aspx?id=346525&version=healthprofessional&language=English&dictionary=Cancer.gov) gemcitabine chemotherapy in patients with newly diagnosed pancreatic cancer.[[16](#cit/section_5.16)] Seven participants were initially enrolled. When safety was confirmed, an additional seven participants were enrolled. Twelve of the 14 enrolled participants completed the phase I pharmacokinetic evaluation. The evaluation consisted of IV vitamin C and gemcitabine pharmacokinetic measurements, each as single [drugs](/Common/PopUps/popDefinition.aspx?id=348921&version=healthprofessional&language=English&dictionary=Cancer.gov), and then followed by the pharmacokinetic measurement of IV vitamin C combined with gemcitabine. IV vitamin C administration did not interfere with gemcitabine.

In May 2019, a phase I study was published that examined the safety, [pharmacokinetics](/Common/PopUps/popDefinition.aspx?id=44324&version=healthprofessional&language=English&dictionary=Cancer.gov), and efficacy of high-dose IV vitamin C combined with the [combination chemotherapy](/Common/PopUps/popDefinition.aspx?id=45650&version=healthprofessional&language=English&dictionary=Cancer.gov) [regimens](/Common/PopUps/popDefinition.aspx?id=45864&version=healthprofessional&language=English&dictionary=Cancer.gov) mFOLFOX6 ([oxaliplatin](/Common/PopUps/popDefinition.aspx?id=45465&version=healthprofessional&language=English&dictionary=Cancer.gov) + leucovorin + [fluorouracil](/Common/PopUps/popDefinition.aspx?id=635764&version=healthprofessional&language=English&dictionary=Cancer.gov)) or [FOLFIRI](/Common/PopUps/popDefinition.aspx?id=635807&version=healthprofessional&language=English&dictionary=Cancer.gov) (leucovorin + fluorouracil + irinotecan hydrochloride). This study consisted of 36 patients with [metastatic](/Common/PopUps/popDefinition.aspx?id=44058&version=healthprofessional&language=English&dictionary=Cancer.gov) [colorectal cancer](/Common/PopUps/popDefinition.aspx?id=444983&version=healthprofessional&language=English&dictionary=Cancer.gov) or [gastric cancer](/Common/PopUps/popDefinition.aspx?id=454513&version=healthprofessional&language=English&dictionary=Cancer.gov). The main goal was to determine the [maximum-tolerated dose](/Common/PopUps/popDefinition.aspx?id=546597&version=healthprofessional&language=English&dictionary=Cancer.gov) and the recommended [phase II](/Common/PopUps/popDefinition.aspx?id=45831&version=healthprofessional&language=English&dictionary=Cancer.gov) dose of ascorbic acid with coadministration of either mFOLFOX6 or FOLFIRI. Patients received chemotherapy treatment on a 14-day cycle with vitamin C infusions occurring for 3 consecutive days for 3 hours at a time. For the dose-escalation portion of the study, ascorbic acid doses ranged from 0.2 g/kg to 1.5 g/kg. To determine the optimal administration rate of ascorbic acid, patient cohorts received infusion rates set at 0.6 g/min, 0.8 g/min, or 1 g/min. The study showed no [dose-limiting](/Common/PopUps/popDefinition.aspx?id=44170&version=healthprofessional&language=English&dictionary=Cancer.gov) toxicity for all doses and dosing rates; thus a maximum-tolerated dose was not reached, leading to a recommended phase II dose of 1.5 g/kg for ascorbic acid. Overall, no severe adverse reactions occurred, and the treatments were deemed safe and tolerable. A randomized [phase III trial](/Common/PopUps/popDefinition.aspx?id=45833&version=healthprofessional&language=English&dictionary=Cancer.gov) ([NCT02969681](/clinicaltrials/NCT02969681)) is being conducted to determine the clinical efficacy of ascorbic acid with mFOLFOX6 with or without [bevacizumab](/Common/PopUps/popDefinition.aspx?id=46115&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients with metastatic colorectal cancer.[[17](#cit/section_5.17)]

A [phase II clinical trial](/Common/PopUps/popDefinition.aspx?id=45831&version=healthprofessional&language=English&dictionary=Cancer.gov) published in 2024 evaluated the clinical benefit of combining pharmacologic IV vitamin C with [docetaxel](/Common/PopUps/popDefinition.aspx?id=45382&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients with progressive metastatic castration-resistant prostate cancer. Forty-seven patients were randomly assigned 2:1 to receive docetaxel (75 mg/m2 IV) with either pharmacologic IV vitamin C (1 g/kg) or placebo. The study found that the addition of the vitamin C to docetaxel did not improve PSA response, toxicity, or other clinical outcomes when compared with docetaxel alone.[[18](#cit/section_5.18)]

Another phase II clinical trial published in 2024 assessed the effect of pharmacological ascorbate (P-AscH-) combined with gemcitabine and nab-paclitaxel in patients with stage IV pancreatic cancer. Thirty-four patients were randomly assigned 1:1 to receive gemcitabine and nab-paclitaxel only or gemcitabine and nab-paclitaxel with [concomitant](/Common/PopUps/popDefinition.aspx?id=635464&version=healthprofessional&language=English&dictionary=Cancer.gov) P-AscH- (75 g three times weekly). The study found that the addition of P-AscH− to gemcitabine and nab-paclitaxel prolonged OS and PFS in patients with metastatic pancreatic cancer, without detected detriment to quality of life or added toxicity.[[19](#cit/section_5.19)]

Table 1. Clinical Studies of Ascorbate with Chemotherapya

| Reference | Trial Design | [Condition](/Common/PopUps/popDefinition.aspx?id=651193&version=healthprofessional&language=English&dictionary=Cancer.gov) or Cancer Type | Dose | Treatment Groups (Enrolled; Treated; Placebo or No Treatment Control)b | Results | [Concurrent Therapy](/Common/PopUps/popDefinition.aspx?id=44011&version=healthprofessional&language=English&dictionary=Cancer.gov) Used | Level of Evidence Scorec |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | | | | |
| aFor additional information and definition of terms, see text and the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"). | | | | | | | |
| bNumber of patients treated plus number of patient controls may not equal number of patients enrolled; number of patients enrolled equals number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated equals number of enrolled patients who were given the treatment being studied AND for whom results were reported. | | | | | | | |
| cFor information about [levels of evidence](/Common/PopUps/popDefinition.aspx?id=446533&version=healthprofessional&language=English&dictionary=Cancer.gov) analysis and scores, see [Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies](/publications/pdq/levels-evidence/cam). | | | | | | | |
| [[16](#cit/section_5.16)] | Phase I/IIA trial | Newly diagnosed pancreatic cancer | 6 doses of 25–75 g/infusion for phase I and 64 doses of 100 g/infusion for phase II | 14; 12; none | Ascorbic acid did not interfere with gemcitabine pharmacokinetics | Gemcitabine | [2Dii](/Common/PopUps/popDefinition.aspx?id=335136&version=HealthProfessional&language=English) |
| [[12](#cit/section_5.12)] | Phase I, open label trial | Metastatic stage IV pancreatic cancer | 50 g/infusion, 75 g/infusion, or 100 g/infusion 3x/wk for 8 wk | 14; 14 (9 analyzed); none | Ascorbic acid was well tolerated with gemcitabine and erlotinib | Gemcitabine, erlotinib | [2Dii](/Common/PopUps/popDefinition.aspx?id=335136&version=HealthProfessional&language=English) |
| [[13](#cit/section_5.13)] | Phase I, open label trial | Stage IV pancreatic [adenocarcinoma](/Common/PopUps/popDefinition.aspx?id=46216&version=healthprofessional&language=English&dictionary=Cancer.gov) | 15 g/wk until the plasma level reached at least 350 mg/dL (20 mM) | 15; 11 (9 completed); none | Ascorbate acid was well tolerated with gemcitabine | Gemcitabine | [2Dii](/Common/PopUps/popDefinition.aspx?id=335136&version=HealthProfessional&language=English) |
| [[14](#cit/section_5.14)] | Pilot phase I/IIA trial | Stage III/IV [ovarian cancer](/Common/PopUps/popDefinition.aspx?id=445074&version=healthprofessional&language=English&dictionary=Cancer.gov) | Up to 75 g or 100 g 2x/wk for 12 mo | 27; 14 (chemotherapy), 13 (chemotherapy and intravenous vitamin C); none | Ascorbate acid added to carboplatin and paclitaxel therapy reduced chemotherapy-related toxicities | Carboplatin, paclitaxel | [2C](/Common/PopUps/popDefinition.aspx?id=335134&version=HealthProfessional&language=English) |

Trials of high-dose IV vitamin C combined with other drugs are ongoing.[[12](#cit/section_5.12),[14](#cit/section_5.14)] A number of studies have included small doses of IV ascorbic acid treatment (1,000 mg) with [arsenic trioxide](/Common/PopUps/popDefinition.aspx?id=46018&version=healthprofessional&language=English&dictionary=Cancer.gov) regimens, with mixed results. For study results, see [Table 2](/about-cancer/treatment/cam/hp/vitamin-c-pdq#_102).

Table 2. Clinical Studies of Ascorbate in Arsenic Trioxide–Containing Regimensa

| Reference | Trial Design | Condition or Cancer Type | Dose | Treatment Groups (Enrolled; Treated; Placebo or No Treatment Control)b | Results | Concurrent Therapy Used | Level of Evidence Scorec |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| N = number of patients; RCT = randomized controlled trial. | | | | | | | |
| aFor additional information and definition of terms, see text and the [NCI Dictionary of Cancer Terms](https://www.cancer.gov/publications/dictionaries/cancer-terms/ "https://www.cancer.gov/publications/dictionaries/cancer-terms/"). | | | | | | | |
| bNumber of patients treated plus number of patient controls may not equal number of patients enrolled; number of patients enrolled equals number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated equals number of enrolled patients who were given the treatment being studied AND for whom results were reported. | | | | | | | |
| cFor information about levels of evidence analysis and scores, see [Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies](/publications/pdq/levels-evidence/cam). | | | | | | | |
| [[20](#cit/section_5.20)] | RCT | [Multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=healthprofessional&language=English&dictionary=Cancer.gov) | 1,000 mg | 48; arm 1 (N = 16), arm 2 (N = 17), arm 3 (N = 15); none | The addition of arsenic trioxide and ascorbic acid to high-dose [melphalan](/Common/PopUps/popDefinition.aspx?id=45957&version=healthprofessional&language=English&dictionary=Cancer.gov) was reported safe and well tolerated | Melphalan | [1iiDii](/Common/PopUps/popDefinition.aspx?id=335129&version=HealthProfessional&language=English) |
| [[21](#cit/section_5.21)] | [Phase II](/Common/PopUps/popDefinition.aspx?id=45831&version=healthprofessional&language=English&dictionary=Cancer.gov), open label | [Relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=healthprofessional&language=English&dictionary=Cancer.gov) or [refractory](/Common/PopUps/popDefinition.aspx?id=350245&version=healthprofessional&language=English&dictionary=Cancer.gov) multiple myeloma | 1,000 mg | 20; 20; none | Clinical efficacy and tolerability with arsenic trioxide, [dexamethasone](/Common/PopUps/popDefinition.aspx?id=45262&version=healthprofessional&language=English&dictionary=Cancer.gov), and ascorbic acid was reported | Dexamethasone | [3iDii](/Common/PopUps/popDefinition.aspx?id=335142&version=HealthProfessional&language=English) |
| [[22](#cit/section_5.22)] | Phase I/II, open label | Relapsed or refractory multiple myeloma | 1,000 mg | 22; 22; none | Arsenic trioxide, [bortezomib](/Common/PopUps/popDefinition.aspx?id=269133&version=healthprofessional&language=English&dictionary=Cancer.gov), and ascorbic acid was well tolerated with signs of clinical efficacy | Bortezomib | [3iDii](/Common/PopUps/popDefinition.aspx?id=335142&version=HealthProfessional&language=English) |
| [[23](#cit/section_5.23)] | Phase II | Relapsed or refractory multiple myeloma | 1,000 mg | 65; 65; none | Melphalan, arsenic trioxide, and ascorbic acid was effective and well tolerated | Melphalan | [3iDii](/Common/PopUps/popDefinition.aspx?id=335142&version=HealthProfessional&language=English) |
| [[24](#cit/section_5.24)] | Phase II | Refractory metastatic colorectal carcinoma | 1,000 mg | 5; 5; none | Patients developed moderate to severe toxic side effects without clinical response | None | [3iDii](/Common/PopUps/popDefinition.aspx?id=335142&version=HealthProfessional&language=English) |
| [[25](#cit/section_5.25)] | Phase II, open label | Metastatic [melanoma](/Common/PopUps/popDefinition.aspx?id=45135&version=healthprofessional&language=English&dictionary=Cancer.gov) | 1,000 mg | 11; 10; none | Patients developed toxic side effects without clinical response | [Temozolomide](/Common/PopUps/popDefinition.aspx?id=45387&version=healthprofessional&language=English&dictionary=Cancer.gov) | [3iDii](/Common/PopUps/popDefinition.aspx?id=335142&version=HealthProfessional&language=English) |

Informed by their preclinical data,[[21](#cit/section_5.21)] researchers at the University of Iowa treated patients with [non-small cell lung](/Common/PopUps/popDefinition.aspx?id=45323&version=healthprofessional&language=English&dictionary=Cancer.gov) carcinoma (NSCLC) and [glioblastoma multiforme](/Common/PopUps/popDefinition.aspx?id=45699&version=healthprofessional&language=English&dictionary=Cancer.gov) (GBM) in two pilot clinical trials ([NCT02420314](/clinicaltrials/NCT02420314) and [NCT01752491](/clinicaltrials/NCT01752491)).[[26](#cit/section_5.26)] Participants in both trials were given [conventional therapy](/Common/PopUps/popDefinition.aspx?id=44198&version=healthprofessional&language=English&dictionary=Cancer.gov) plus IV vitamin C, with dosing individualized to achieve a 20 mM peak plasma concentration of ascorbate in each patient. The GBM study was a phase I design with 13 total patients. IV vitamin C was given with both [radiation therapy](/Common/PopUps/popDefinition.aspx?id=44971&version=healthprofessional&language=English&dictionary=Cancer.gov) and [temozolomide](/Common/PopUps/popDefinition.aspx?id=45387&version=healthprofessional&language=English&dictionary=Cancer.gov) and toxicity, progression-free survival, and overall survival all compared favorably to the outcomes of historical controls. The NSCLC trial was a [phase II](/Common/PopUps/popDefinition.aspx?id=45831&version=healthprofessional&language=English&dictionary=Cancer.gov) design of 14 patients with advanced cancer who received both chemotherapy and IV vitamin C (median maximum plasma concentration, 16.4 mM). The disease control and confirmed [objective response](/Common/PopUps/popDefinition.aspx?id=44067&version=healthprofessional&language=English&dictionary=Cancer.gov) rates of the study group again compared favorably with those of historical controls. Limitations of these studies included the use of historical controls and small numbers of enrolled participants.

Various trials of high-dose IV vitamin C with other drugs are ongoing. There are currently five trials being conducted by researchers at the University of Iowa; four phase II studies and one phase IB/II study. The four phase II clinical trials are investigating the efficacy of high-dose ascorbate combined with standard anticancer regimens. The studies are exploring the combination of high-dose ascorbate with the following:

- Standard non-small cell lung cancer therapy, including radiation therapy, carboplatin, and paclitaxel ([NCT02905591](/clinicaltrials/NCT02905591)).
- [Standard therapy](/Common/PopUps/popDefinition.aspx?id=44930&version=healthprofessional&language=English&dictionary=Cancer.gov) for metastatic pancreatic adenocarcinoma, including gemcitabine and nab-paclitaxel ([NCT02905578](/clinicaltrials/NCT02905578)).
- Standard therapy for [localized](/Common/PopUps/popDefinition.aspx?id=45754&version=healthprofessional&language=English&dictionary=Cancer.gov) pancreatic adenocarcinoma with gemcitabine and radiation therapy ([NCT03541486](/clinicaltrials/NCT03541486)).
- Standard therapy for glioblastoma multiforme, including temozolomide and radiation therapy ([NCT02344355](/clinicaltrials/NCT02344355)).

Another phase IB/II trial ([NCT03508726](/clinicaltrials/NCT03508726)) is studying the safety and efficacy of high-dose ascorbate with preoperative radiation therapy in patients with [locally advanced](/Common/PopUps/popDefinition.aspx?id=45955&version=healthprofessional&language=English&dictionary=Cancer.gov) [soft tissue sarcoma](/Common/PopUps/popDefinition.aspx?id=46584&version=healthprofessional&language=English&dictionary=Cancer.gov).

Several studies have included IV ascorbic acid treatment at a fixed dose of 1,000 mg with arsenic trioxide regimens, with mixed results. Researchers using this approach suggested that the [pro-oxidant](/Common/PopUps/popDefinition.aspx?id=372940&version=healthprofessional&language=English&dictionary=Cancer.gov) properties of IV ascorbic acid may have helped to increase the effects of arsenic trioxide by sensitization of [malignant](/Common/PopUps/popDefinition.aspx?id=45772&version=healthprofessional&language=English&dictionary=Cancer.gov) cells to arsenic’s cytotoxic effects.[[27](#cit/section_5.27)] The combination therapies were well tolerated and suggested beneficial effects in patients with multiple myeloma, although the specific contribution of vitamin C could not be determined.[[20](#cit/section_5.20)-[23](#cit/section_5.23)] However, similar combination regimens resulted in severe side effects, [disease progression](/Common/PopUps/popDefinition.aspx?id=45669&version=healthprofessional&language=English&dictionary=Cancer.gov), and no anticancer effect in patients with refractory metastatic colorectal cancer [[24](#cit/section_5.24)] and metastatic melanoma.[[25](#cit/section_5.25)] Because these were not placebo-controlled trials, the extent that ascorbate contributed to the toxicity or efficacy demonstrated in these studies is unclear.

### Current Clinical Trials

Use our [advanced clinical trial search](https://www.cancer.gov/research/participate/clinical-trials-search/advanced "https://www.cancer.gov/research/participate/clinical-trials-search/advanced") to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. [General information](https://www.cancer.gov/research/participate/clinical-trials "https://www.cancer.gov/research/participate/clinical-trials") about clinical trials is also available.

###### References

1. Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4430016&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4430016&dopt=Abstract")
2. Cameron E, Campbell A, Jack T: The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact 11 (5): 387-93, 1975. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1104207&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1104207&dopt=Abstract")
3. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1068480&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1068480&dopt=Abstract")
4. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=279931&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=279931&dopt=Abstract")
5. Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=384241&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=384241&dopt=Abstract")
6. Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3880867&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3880867&dopt=Abstract")
7. Padayatty SJ, Riordan HD, Hewitt SM, et al.: Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174 (7): 937-42, 2006. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16567755&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16567755&dopt=Abstract")
8. Yeom CH, Jung GC, Song KJ: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22 (1): 7-11, 2007. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17297243&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17297243&dopt=Abstract")
9. Nielsen TK, Højgaard M, Andersen JT, et al.: Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial. Transl Androl Urol 6 (3): 517-528, 2017. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28725594&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28725594&dopt=Abstract")
10. Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15068981&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15068981&dopt=Abstract")
11. Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18544557&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18544557&dopt=Abstract")
12. Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22272248&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22272248&dopt=Abstract")
13. Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23381814&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23381814&dopt=Abstract")
14. Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24500406&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24500406&dopt=Abstract")
15. Hoffer LJ, Robitaille L, Zakarian R, et al.: High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One 10 (4): e0120228, 2015. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25848948&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25848948&dopt=Abstract")
16. Polireddy K, Dong R, Reed G, et al.: High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Sci Rep 7 (1): 17188, 2017. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29215048&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29215048&dopt=Abstract")
17. Wang F, He MM, Wang ZX, et al.: Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer 19 (1): 460, 2019. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31096937&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31096937&dopt=Abstract")
18. Paller CJ, Zahurak ML, Mandl A, et al.: High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. Cancer Res Commun 4 (8): 2174-2182, 2024. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39076107&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39076107&dopt=Abstract")
19. Bodeker KL, Smith BJ, Berg DJ, et al.: A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. Redox Biol 77: 103375, 2024. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39369582&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39369582&dopt=Abstract")
20. Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19041063&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19041063&dopt=Abstract")
21. Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16720927&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16720927&dopt=Abstract")
22. Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17363530&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17363530&dopt=Abstract")
23. Berenson JR, Boccia R, Siegel D, et al.: Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135 (2): 174-83, 2006. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17010047&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17010047&dopt=Abstract")
24. Subbarayan PR, Lima M, Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 46 (4): 557-61, 2007. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17497326&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17497326&dopt=Abstract")
25. Bael TE, Peterson BL, Gollob JA: Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 18 (2): 147-51, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18337652&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18337652&dopt=Abstract")
26. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 32 (2): 268, 2017. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28810149&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28810149&dopt=Abstract")
27. Campbell RA, Sanchez E, Steinberg JA, et al.: Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 138 (4): 467-78, 2007. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17587338&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17587338&dopt=Abstract")

## Adverse Effects

[Intravenous](/Common/PopUps/popDefinition.aspx?id=46682&version=healthprofessional&language=English&dictionary=Cancer.gov) (IV) high-[dose](/Common/PopUps/popDefinition.aspx?id=44664&version=healthprofessional&language=English&dictionary=Cancer.gov) [ascorbic acid](/Common/PopUps/popDefinition.aspx?id=439436&version=healthprofessional&language=English&dictionary=Cancer.gov) has been generally well tolerated in [clinical trials](/Common/PopUps/popDefinition.aspx?id=45961&version=healthprofessional&language=English&dictionary=Cancer.gov).[[1](#cit/section_6.1)-[9](#cit/section_6.9)] [Renal failure](/Common/PopUps/popDefinition.aspx?id=462925&version=healthprofessional&language=English&dictionary=Cancer.gov) after ascorbic acid treatment has been reported in patients with preexisting renal [disorders](/Common/PopUps/popDefinition.aspx?id=407758&version=healthprofessional&language=English&dictionary=Cancer.gov).[[10](#cit/section_6.10)] One study reported [fluid](/Common/PopUps/popDefinition.aspx?id=44669&version=healthprofessional&language=English&dictionary=Cancer.gov) overload related to ascorbic acid [infusion](/Common/PopUps/popDefinition.aspx?id=45738&version=healthprofessional&language=English&dictionary=Cancer.gov), but this may be caused by the delivery method and not the product.[[11](#cit/section_6.11)]

[Case reports](/Common/PopUps/popDefinition.aspx?id=44007&version=healthprofessional&language=English&dictionary=Cancer.gov) have indicated that patients with [glucose-6-phosphate dehydrogenase (G-6-PD) deficiency](/Common/PopUps/popDefinition.aspx?id=748114&version=healthprofessional&language=English&dictionary=Cancer.gov) should not receive high doses of [vitamin C](/Common/PopUps/popDefinition.aspx?id=439435&version=healthprofessional&language=English&dictionary=Cancer.gov) because of the risk of developing [hemolysis](/Common/PopUps/popDefinition.aspx?id=687883&version=healthprofessional&language=English&dictionary=Cancer.gov).[[12](#cit/section_6.12)-[14](#cit/section_6.14)]

[Administration](/Common/PopUps/popDefinition.aspx?id=478733&version=healthprofessional&language=English&dictionary=Cancer.gov) of IV vitamin C at high doses has been shown to interfere with the measurement of [serum](/Common/PopUps/popDefinition.aspx?id=44088&version=healthprofessional&language=English&dictionary=Cancer.gov) biochemical parameters. A study of the administration of high-dose IV vitamin C has been observed to interfere with certain laboratory tests such as strip-based [glucose](/Common/PopUps/popDefinition.aspx?id=44033&version=healthprofessional&language=English&dictionary=Cancer.gov) meters, showing false elevations in the glucose measurements.[[15](#cit/section_6.15),[16](#cit/section_6.16)]

### Drug Interactions

When administered in high doses, vitamin C may result in adverse interactions with some anticancer agents. These interactions have primarily been detected in [preclinical studies](/Common/PopUps/popDefinition.aspx?id=44517&version=healthprofessional&language=English&dictionary=Cancer.gov). Two early clinical studies evaluated the safety of combining high-dose IV ascorbate with [gemcitabine](/Common/PopUps/popDefinition.aspx?id=508951&version=healthprofessional&language=English&dictionary=Cancer.gov) in patients with stage IV [pancreatic cancer](/Common/PopUps/popDefinition.aspx?id=44521&version=healthprofessional&language=English&dictionary=Cancer.gov). The combination therapy was well tolerated by patients, and no significant adverse events were reported.[[9](#cit/section_6.9),[17](#cit/section_6.17)]

*[In vitro](/Common/PopUps/popDefinition.aspx?id=45733&version=healthprofessional&language=English&dictionary=Cancer.gov)* and *[in vivo](/Common/PopUps/popDefinition.aspx?id=46352&version=healthprofessional&language=English&dictionary=Cancer.gov)* [animal studies](/Common/PopUps/popDefinition.aspx?id=454774&version=healthprofessional&language=English&dictionary=Cancer.gov) have suggested that combining [oral](/Common/PopUps/popDefinition.aspx?id=44068&version=healthprofessional&language=English&dictionary=Cancer.gov) vitamin C with [bortezomib](/Common/PopUps/popDefinition.aspx?id=269133&version=healthprofessional&language=English&dictionary=Cancer.gov) interferes with the drug’s ability to act as a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=healthprofessional&language=English&dictionary=Cancer.gov) and blocks bortezomib-initiated [apoptosis](/Common/PopUps/popDefinition.aspx?id=46524&version=healthprofessional&language=English&dictionary=Cancer.gov).[[18](#cit/section_6.18)-[20](#cit/section_6.20)] This interference occurred even with the oral administration of vitamin C (40 [mg](/Common/PopUps/popDefinition.aspx?id=44213&version=healthprofessional&language=English&dictionary=Cancer.gov)/[kg](/Common/PopUps/popDefinition.aspx?id=44576&version=healthprofessional&language=English&dictionary=Cancer.gov)/day) to animals. Studies in [cell culture](/Common/PopUps/popDefinition.aspx?id=556412&version=healthprofessional&language=English&dictionary=Cancer.gov) and performed by adding [blood](/Common/PopUps/popDefinition.aspx?id=270735&version=healthprofessional&language=English&dictionary=Cancer.gov) [plasma](/Common/PopUps/popDefinition.aspx?id=45839&version=healthprofessional&language=English&dictionary=Cancer.gov) from healthy volunteers given oral vitamin C (1 [g](/Common/PopUps/popDefinition.aspx?id=373014&version=healthprofessional&language=English&dictionary=Cancer.gov)/day) also showed a [significant](/Common/PopUps/popDefinition.aspx?id=390271&version=healthprofessional&language=English&dictionary=Cancer.gov) decrease in bortezomib’s growth inhibitory effect on [multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=healthprofessional&language=English&dictionary=Cancer.gov) cells. Another study found similar results. Plasma from healthy volunteers who took 1 g of oral vitamin C per day was shown to decrease bortezomib growth inhibition in multiple myeloma cells and to block its inhibitory effect on 20S proteasome activity.[[20](#cit/section_6.20)] However, a study that utilized mice harboring human [prostate cancer](/Common/PopUps/popDefinition.aspx?id=445079&version=healthprofessional&language=English&dictionary=Cancer.gov) cell [xenografts](/Common/PopUps/popDefinition.aspx?id=44095&version=healthprofessional&language=English&dictionary=Cancer.gov) failed to find any significant effect of oral vitamin C (40 mg/kg/day or 500 mg/kg/day) on the [tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) growth inhibitory action of bortezomib.[[21](#cit/section_6.21)] Because IV administration of vitamin C is known to produce higher concentrations of ascorbate than oral administration, these results should be a warning for patients with [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov) who are receiving treatment with bortezomib. Study results of the co-administration of IV vitamin C and bortezomib in humans would help guide clinical recommendations.

Several studies have been performed to assess the potential [synergistic](/Common/PopUps/popDefinition.aspx?id=330184&version=healthprofessional&language=English&dictionary=Cancer.gov) or inhibitory action of vitamin C on certain [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=healthprofessional&language=English&dictionary=Cancer.gov) [drugs](/Common/PopUps/popDefinition.aspx?id=348921&version=healthprofessional&language=English&dictionary=Cancer.gov), with variable results. A series of studies in cell culture and in animals bearing tumors has shown that when given at high concentrations or dosages, dehydroascorbic acid (an oxidized form of vitamin C) can interfere with the [cytotoxic](/Common/PopUps/popDefinition.aspx?id=44020&version=healthprofessional&language=English&dictionary=Cancer.gov) effects of several chemotherapy drugs.[[22](#cit/section_6.22)] However, dehydroascorbic acid is generally present only at low concentrations in [dietary supplements](/Common/PopUps/popDefinition.aspx?id=373932&version=healthprofessional&language=English&dictionary=Cancer.gov) and fresh foods.

###### References

1. Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15068981&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15068981&dopt=Abstract")
2. Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18544557&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18544557&dopt=Abstract")
3. Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18678913&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18678913&dopt=Abstract")
4. Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22272248&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22272248&dopt=Abstract")
5. Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16720927&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16720927&dopt=Abstract")
6. Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17363530&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17363530&dopt=Abstract")
7. Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19041063&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19041063&dopt=Abstract")
8. Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24500406&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24500406&dopt=Abstract")
9. Polireddy K, Dong R, Reed G, et al.: High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Sci Rep 7 (1): 17188, 2017. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29215048&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29215048&dopt=Abstract")
10. Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20628650&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20628650&dopt=Abstract")
11. Nielsen TK, Højgaard M, Andersen JT, et al.: Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial. Transl Androl Urol 6 (3): 517-528, 2017. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28725594&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28725594&dopt=Abstract")
12. Campbell GD, Steinberg MH, Bower JD: Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 82 (6): 810, 1975. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1138591&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1138591&dopt=Abstract")
13. Mehta JB, Singhal SB, Mehta BC: Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 336 (8720): 944, 1990. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1976956&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1976956&dopt=Abstract")
14. Rees DC, Kelsey H, Richards JD: Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306 (6881): 841-2, 1993. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8490379&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8490379&dopt=Abstract")
15. Katzman BM, Kelley BR, Deobald GR, et al.: Unintended Consequence of High-Dose Vitamin C Therapy for an Oncology Patient: Evaluation of Ascorbic Acid Interference With Three Hospital-Use Glucose Meters. J Diabetes Sci Technol 15 (4): 897-900, 2021. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32506941&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32506941&dopt=Abstract")
16. Martinello F, da Silva EL: Ascorbic acid interference in the measurement of serum biochemical parameters: in vivo and in vitro studies. Clin Biochem 39 (4): 396-403, 2006. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16403487&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16403487&dopt=Abstract")
17. Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23381814&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23381814&dopt=Abstract")
18. Zou W, Yue P, Lin N, et al.: Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12 (1): 273-80, 2006. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16397052&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16397052&dopt=Abstract")
19. Llobet D, Eritja N, Encinas M, et al.: Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 19 (2): 115-24, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18176107&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18176107&dopt=Abstract")
20. Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19369963&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19369963&dopt=Abstract")
21. Bannerman B, Xu L, Jones M, et al.: Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 68 (5): 1145-54, 2011. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21400028&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21400028&dopt=Abstract")
22. Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008. [[PUBMED Abstract]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18829561&dopt=Abstract "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18829561&dopt=Abstract")

## Summary of the Evidence for Intravenous Vitamin C

To assist readers in evaluating the results of human studies of integrative, alternative, and complementary therapies for [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=healthprofessional&language=English&dictionary=Cancer.gov), the strength of the evidence (i.e., the [levels of
evidence](/Common/PopUps/popDefinition.aspx?id=446533&version=healthprofessional&language=English&dictionary=Cancer.gov)) associated with each type of treatment is provided whenever
possible. To qualify for a level of evidence [analysis](/Common/PopUps/popDefinition.aspx?id=390238&version=healthprofessional&language=English&dictionary=Cancer.gov), a study must:

- Be published in a [peer-reviewed scientific journal](/Common/PopUps/popDefinition.aspx?id=537399&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Report on a [therapeutic](/Common/PopUps/popDefinition.aspx?id=43985&version=healthprofessional&language=English&dictionary=Cancer.gov) [outcome](/Common/PopUps/popDefinition.aspx?id=467853&version=healthprofessional&language=English&dictionary=Cancer.gov) or outcomes, such as [tumor](/Common/PopUps/popDefinition.aspx?id=46634&version=healthprofessional&language=English&dictionary=Cancer.gov) [response](/Common/PopUps/popDefinition.aspx?id=44085&version=healthprofessional&language=English&dictionary=Cancer.gov), improvement in survival, or measured improvement in [quality of life](/Common/PopUps/popDefinition.aspx?id=45417&version=healthprofessional&language=English&dictionary=Cancer.gov).
- Describe [clinical](/Common/PopUps/popDefinition.aspx?id=44168&version=healthprofessional&language=English&dictionary=Cancer.gov) findings in sufficient detail that a meaningful evaluation can be made.

Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and [scientific](/Common/PopUps/popDefinition.aspx?id=44724&version=healthprofessional&language=English&dictionary=Cancer.gov) strength of the treatment outcomes (i.e., [endpoints](/Common/PopUps/popDefinition.aspx?id=346519&version=healthprofessional&language=English&dictionary=Cancer.gov)) measured. The resulting two scores are then combined to produce an overall score. For an explanation of the scores and additional information about levels of evidence analysis for cancer, see [Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies](/publications/pdq/levels-evidence/cam).

## Latest Updates to This Summary (05/13/2025)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

**[Human/Clinical Studies](/about-cancer/treatment/cam/hp/vitamin-c-pdq#_16)**

Added [text](/about-cancer/treatment/cam/hp/vitamin-c-pdq#_158) to state that a phase II clinical trial published in 2024 evaluated the clinical benefit of combining pharmacologic IV vitamin C with docetaxel in patients with progressive metastatic castration-resistant prostate cancer. Forty-seven patients were randomly assigned 2:1 to receive docetaxel with either pharmacologic IV vitamin C or placebo. The study found that the addition of the vitamin C to docetaxel did not improve prostate-specific antigen response, toxicity, or other clinical outcomes when compared with docetaxel alone (cited Paller et al. as reference 18).

Added [text](/about-cancer/treatment/cam/hp/vitamin-c-pdq#_159) to state that a phase II clinical trial published in 2024 assessed the effect of pharmacological ascorbate (P-AscH-) combined with gemcitabine and nab-paclitaxel in patients with stage IV pancreatic cancer. Thirty-four patients were randomly assigned 1:1 to receive gemcitabine and nab-paclitaxel only or gemcitabine and nab-paclitaxel with concomitant P-AscH-. The study found that the addition of P-AscH- to gemcitabine and nab-paclitaxel prolonged overall survival and progression-free survival in patients with metastatic pancreatic cancer, without detected detriment to quality of life or added toxicity (cited Bodeker et al. as reference 19).

This summary is written and maintained by the [PDQ Integrative, Alternative, and Complementary Therapies Editorial Board](https://www.cancer.gov/publications/pdq/editorial-boards/cam "https://www.cancer.gov/publications/pdq/editorial-boards/cam"), which is
editorially independent of NCI. The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH. More
information about summary policies and the role of the PDQ Editorial Boards in
maintaining the PDQ summaries can be found on the [About This PDQ Summary](/about-cancer/treatment/cam/hp/vitamin-c-pdq#_AboutThis_1) and [PDQ® Cancer Information for Health Professionals](https://www.cancer.gov/publications/pdq "https://www.cancer.gov/publications/pdq") pages.

## About This PDQ Summary

### Purpose of This Summary

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of intravenous vitamin C in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.

### Reviewers and Updates

This summary is reviewed regularly and updated as necessary by the [PDQ Integrative, Alternative, and Complementary Therapies Editorial Board](https://www.cancer.gov/publications/pdq/editorial-boards/cam "https://www.cancer.gov/publications/pdq/editorial-boards/cam"), which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Board members review recently published articles each month to determine whether an article should:

- be discussed at a meeting,
- be cited with text, or
- replace or update an existing article that is already cited.

Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's [Email Us](https://www.cancer.gov/contact/email-us "https://www.cancer.gov/contact/email-us"). Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.

### Levels of Evidence

Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a [formal evidence ranking system](/publications/pdq/levels-evidence/cam) in developing its level-of-evidence designations.

### Permission to Use This Summary

PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”

The preferred citation for this PDQ summary is:

PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Intravenous Vitamin C. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: [https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq](https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq "https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq"). Accessed <MM/DD/YYYY>. [PMID: 26389504]

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in [Visuals Online](https://visualsonline.cancer.gov/ "https://visualsonline.cancer.gov/"), a collection of over 2,000 scientific images.

### Disclaimer

The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the [Managing Cancer Care](https://www.cancer.gov/about-cancer/managing-care "https://www.cancer.gov/about-cancer/managing-care") page.

### Contact Us

More information about contacting us or receiving help with the Cancer.gov website can be found on our [Contact Us for Help](https://www.cancer.gov/contact "https://www.cancer.gov/contact") page. Questions can also be submitted to Cancer.gov through the website’s [Email Us](https://www.cancer.gov/contact/email-us "https://www.cancer.gov/contact/email-us").
